Selling a Medical Technology Company – Maximise Purchase Price, Reduce Risks & Protect Employees

Selling a Medical Technology Company – Maximise Purchase Price, Reduce Risks & Protect Employees

What should I consider when selling my medical technology company? What matters for a high business sale price? And how do I protect my employees during the sale?

You notice it pretty quickly. Once you start looking into the topic of a business sale, there is no stopping. The questions and thoughts just come flooding in. Whether they are general questions like: What is EBITDA and how do I calculate it for my company, or what do I need EBITDA for? all the way to: Do I have to sell my car when I sell my company?

All important questions – but let's rewind to the very beginning. At the start of a sales process:

Ask yourself the following questions before you take the first step towards a business sale:

1. Why do I want to sell (retirement, illness, loss of interest in the company, growth capital)?
2. What are my top three priorities that I want fulfilled in a business sale?
3. Do I want to withdraw completely or take on an advisory or strategic role – am I prepared to relinquish control, even if decisions are made differently in the future than by me?
4. What does my everyday life look like after the sale – professionally and personally?

After asking yourself these questions, we come to the real

Core question: I want to sell my medical technology company – but how?

Selling MedTech – how do I approach it?

Selling a medical technology company is no ordinary M&A process. Here it is not enough to simply put a few figures and a glossy presentation on the table. In MedTech, regulatory compliance determines the purchase price – and that is precisely the biggest hurdle for many sellers. Certificates, MDR transition deadlines, EUDAMED, PRRC, supply chains, international customer relationships, and on top of that the high liability risks for defective products: anyone who is not perfectly prepared will quickly find themselves facing an experienced buyer who uses exactly these points as price depressors.

That is why one thing is clear: You need clean documentation. A comprehensible business plan, clear regulatory roadmaps and a prepared data room are mandatory if you want to achieve a fair and high purchase price at the end.

Starting position – before you approach buyers

Before you contact the first interested party, clarify your own starting position. What is your target scenario and what time horizon is realistic? In MedTech, a sales process typically takes 9 to 18 months. Do you want a Share Deal, in which the manufacturer identity remains intact, or an Asset Deal, which may offer tax advantages but is considerably riskier from a regulatory standpoint? What role do you want to take after closing – completely out or still involved as an advisory board member? And what are absolute no-gos that you do not want to negotiate on – location, brand, employment?

Regulation as a price lever

In no other sector is regulation so directly linked to the purchase price as in MedTech. Buyers pay for predictability. Anyone who can demonstrate that certificates are valid, MDR transition deadlines are being met, EUDAMED data is properly maintained and a PRRC has been appointed removes risk from buyers. The result: fewer renegotiations and a higher multiple. Conversely, unclear documentation and open questions almost automatically lead to discounts.

What really drives the purchase price of a MedTech company?

Beyond regulation, it is always the same factors: recurring revenues (disposables, service contracts, software subscriptions), clean EBITDA figures without one-off effects, secured reimbursement systems, stable supply chains, IP protection and a functioning management team. A buyer does not only look at what exists today, but at the question: How predictable and low-risk are the next five years?

Not every MedTech is the same

An implant manufacturer is assessed on clinical evidence and traceability, an IVD company on performance evaluation and margins, a software company on efficacy and subscription revenues. For OEMs and manufacturers, validated specialist processes count; for distributors, exclusive contracts and tender success. As a seller, you must therefore tailor your equity story precisely to your type.

Deal structure, employees and roadmap

The deal structure is also decisive. A Share Deal is usually the lower-risk route; Asset Deals often contain nasty surprises. Earn-outs can bridge gaps but should be measurable and clearly regulated. At the same time, you must not forget your team: § 613a BGB protects employment relationships, but only if the notification is carried out correctly. Anyone who makes mistakes here risks lawsuits – and buyers immediately see risks. Retention bonuses, phantom shares or clear communication help to stabilise the team during the process.

A professionally prepared data room with financial key figures, regulatory documents, IP evidence and organisational charts is then the key to a smooth Due Diligence. Anyone who has everything readily available signals: We are professional and deal-ready.

Typical deal killers

And finally: the typical pitfalls. Unclear certificate situations, old vigilance problems, excessive customer concentration, single points of failure in the supply chain, no appointed PRRC, neglected EUDAMED data, Asset Deal traps, weak financial figures, an overly "aggressive" M&A legal team or incorrect employee notifications. All of these are points that can be properly prepared – if you know them. Anyone who closes these gaps in advance prevents nasty surprises, shortens the process and ultimately achieves a significantly better purchase price.